
aldosterone and cortisol have similar affinity for MR. However, glucocorticoids circulate at roughly 100 times the level of mineralocorticoids. An enzyme (11-β hydroxsteroid dehydrogenase 1) exists in mineralocorticoid target tissues to prevent overstimulation by glucocorticoids.

**[0005]** When administered to subjects in need thereof, steroids can provide both intended therapeutic effects. as well as negative side effects. What is needed in the art are new compositions and methods for selectively modulating GR Surprisingly, the present invention meets these and other needs.

## BRIEF SUMMARY ~~OF THE INVENTION~~

**[0006]** In one example, the present disclosure provides a compound of formula I:




(I)

or a pharmaceutically acceptable salt thereof,

wherein

$R^1$ is H or $C_{1-6}$ alkyl;

$L^1$ is $C_{1-4}$ alkylene;

$Ar^1$ is a $C_{6-12}$ aryl or 5-10 membered heteroaryl having 1-4 heteroatoms selected from N, O, and S, each of which is optionally substituted with 1-3 $R^a$ groups;

each $R^a$ is independently H, halogen, $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, $C_{1-4}$ haloalkyl, $C_{1-4}$ haloalkoxy, $-SO_2R^{a1}$, or $-NR^{a1}R^{a2}$;

$R^{a1}$ and $R^{a2}$ are each independently H or $C_{1-4}$ alkyl; or $R^{a1}$ and $R^{a2}$ when attached to a nitrogen atom are combined to form a 3-6 membered heterocycle having 1-2 heteroatoms selected from N, O, and S, which is optionally substituted with 1-2 $R^{a3}$;

each $R^{a3}$ is independently H, halogen, $C_{1-4}$ alkyl, or $C_{1-4}$ alkoxy;

$Ar^2$ is a $C_{6-12}$ aryl or 5-10 membered heteroaryl having 1-4 heteroatoms selected from N, O, and S, each of which is optionally substituted with 1-4 $R^b$ groups;

each $R^b$ is independently H, halogen, CN, hydroxy, $C_{1-4}$ alkyl, $C_{2-4}$ alkenyl, $C_{2-4}$ alkynyl, $C_{1-4}$ alkoxy, $C_{1-4}$ alkoxy-$C_{1-4}$ alkyl, $C_{1-4}$ hydroxyalkyl, $C_{1-4}$ haloalkyl, $C_{1-4}$ haloalkoxy, $-OR^{b4}$, $-NR^{b1}R^{b2}$, $-C(O)R^{b1}$, $-C(O)OR^{b1}$, $-OC(O)R^{b1}$, $-C(O)NR^{b1}R^{b2}$, $-NR^{b1}C(O)R^{b2}$, $-SO_2R^{b1}$, $-SO_2NR^{b1}R^{b2}$, or $C_{3-6}$ cycloalkyl;


alternatively, two $R^b$ groups on adjacent ring atoms can be combined to form a $C_{5-8}$ cycloalkyl or a 5-8 membered heterocycle having 1-2 heteroatoms selected from N, O, and S;

$R^{b1}$ and $R^{b2}$ are each independently H or $C_{1-4}$ alkyl; or $R^{b1}$ and $R^{b2}$ when attached to a nitrogen atom are combined to form a 3-6 membered heterocycle having 1-2 heteroatoms selected from N, O, and S, which is optionally substituted with 1-2 $R^{b3}$;

each $R^{b3}$ is independently H, halogen, $C_{1-4}$ alkyl, or $C_{1-4}$ alkoxy; and

each $R^{b4}$ is independently $C_{1-4}$ hydroxyalkyl, $C_{1-4}$ alkoxy-$C_{1-4}$ alkyl, $C_{3-6}$ cycloalkyl or $C_{3-6}$ cycloalkyl-$C_{1-4}$ alkyl.

In one ~~aspect~~example, the present ~~invention~~ disclosure provides a compound of formula I:



(I)

or a pharmaceutically acceptable salt thereof, or an isomer thereof,

wherein

$R^1$ is H or $C_{1-6}$ alkyl;

$L^1$ is $C_{1-4}$ alkylene;

$Ar^1$ is a $C_{6-12}$ aryl or 5-10 membered heteroaryl having 1-4 heteroatoms selected from N, O, and S, each of which is optionally substituted with 1-3 $R^a$ groups;

each $R^a$ is independently H, halogen, $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, $C_{1-4}$ haloalkyl, $C_{1-4}$ haloalkoxy, $-SO_2R^{a1}$, or $-NR^{a1}R^{a2}$;

$R^{a1}$ and $R^{a2}$ are each independently H or $C_{1-4}$ alkyl; or $R^{a1}$ and $R^{a2}$ when attached to a nitrogen atom are combined to form a 3-6 membered heterocycle having 1-2 heteroatoms selected from N, O, and S, which is optionally substituted with 1-2 $R^{a3}$;

each $R^{a3}$ is independently H, halogen, $C_{1-4}$ alkyl, or $C_{1-4}$ alkoxy;

$Ar^2$ is a $C_{6-12}$ aryl or 5-10 membered heteroaryl having 1-4 heteroatoms selected from N, O, and S, each of which is optionally substituted with 1-4 $R^b$ groups;

each $R^b$ is independently H, halogen, CN, hydroxy, $C_{1-4}$ alkyl, $C_{2-4}$ alkenyl, $C_{2-4}$ alkynyl, $C_{1-4}$ alkoxy, $C_{1-4}$ alkoxy-$C_{1-4}$ alkyl, $C_{1-4}$ hydroxyalkyl, $C_{1-4}$ haloalkyl,

$C_{1-4}$ haloalkoxy, $-OR^{b4}$, $-NR^{b1}R^{b2}$, $-C(O)R^{b1}$, $-C(O)OR^{b1}$, $-OC(O)R^{b1}$, $-C(O)NR^{b1}R^{b2}$, $-NR^{b1}C(O)R^{b2}$, $-SO_2R^{b1}$, $-SO_2NR^{b1}R^{b2}$, or $C_{3-6}$ cycloalkyl;

alternatively, two $R^b$ groups on adjacent ring atoms can be combined to form a $C_{5-8}$ cycloalkyl or a 5-8 membered heterocycle having 1-2 heteroatoms selected from N, O, and S;

$R^{b1}$ and $R^{b2}$ are each independently H or $C_{1-4}$ alkyl; or $R^{b1}$ and $R^{b2}$ when attached to a nitrogen atom are combined to form a 3-6 membered heterocycle having 1-2 heteroatoms selected from N, O, and S, which is optionally substituted with 1-2 $R^{b3}$;

each $R^{b3}$ is independently H, halogen, $C_{1-4}$ alkyl, or $C_{1-4}$ alkoxy; and

each $R^{b4}$ is independently $C_{1-4}$ hydroxyalkyl, $C_{1-4}$ alkoxy-$C_{1-4}$ alkyl, $C_{3-6}$ cycloalkyl or $C_{3-6}$ cycloalkyl-$C_{1-4}$ alkyl.

**[0007]** In a second aspect, the present disclosure provides a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a compound of the disclosure. In a second ~~aspect~~example, the present ~~invention~~ disclosure provides a pharmaceutical composition including one or more pharmaceutically acceptable excipients and the compound of formula I.

**[0008]** In a third aspect, the present disclosure provides a use of a therapeutically effective amount of a compound of the disclosure or a pharmaceutical composition of the disclosure in the manufacture of a medicament for treating a disorder or condition through modulating a glucocorticoid receptor. In a third ~~aspect~~example, the present ~~invention~~ disclosure provides a method of treating a disorder or condition through modulating a glucocorticoid receptor, the method including administering to a subject in need of such treatment, a therapeutically effective amount of the compound of formula I or a pharmaceutical composition of the compound of formula I, thereby treating the disorder or condition.


**[0009]** In a fourth aspect, the present disclosure provides a use of an effective amount of the compound of the disclosure or a pharmaceutical composition of the disclosure in the manufacture of a medicament for treating a disorder or condition through antagonizing a glucocorticoid receptor. In a fourth ~~aspect~~example, the present ~~invention~~ disclosure provides a method of treating a disorder or condition through antagonizing a glucocorticoid receptor, the method including administering to a subject in need of such treatment, an effective amount of the compound of formula I or a pharmaceutical composition of the compound of formula I.

## BRIEF DESCRIPTION OF THE DRAWINGS

**[0010]** FIG. 1 shows a method of preparing the compounds of the present invention.

WHAT IS CLAIMED IS:

1. A compound of formula I:



(I)

or a pharmaceutically acceptable salt thereof~~, or an isomer thereof~~,

wherein

$R^1$ is H or $C_{1-6}$ alkyl;

$L^1$ is $C_{1-4}$ alkylene;

$Ar^1$ is a $C_{6-12}$ aryl or 5-10 membered heteroaryl having 1-4 heteroatoms selected from N, O, and S, each of which is optionally substituted with 1-3 $R^a$ groups;

each $R^a$ is independently H, halogen, $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, $C_{1-4}$ haloalkyl, $C_{1-4}$ haloalkoxy, $-SO_2R^{a1}$, or $-NR^{a1}R^{a2}$;

$R^{a1}$ and $R^{a2}$ are each independently H or $C_{1-4}$ alkyl; or $R^{a1}$ and $R^{a2}$ when attached to a nitrogen atom are combined to form a 3-6 membered heterocycle having 1-2 heteroatoms selected from N, O, and S, which is optionally substituted with 1-2 $R^{a3}$;

each $R^{a3}$ is independently H, halogen, $C_{1-4}$ alkyl, or $C_{1-4}$ alkoxy;

$Ar^2$ is a $C_{6-12}$ aryl or 5-10 membered heteroaryl having 1-4 heteroatoms selected from N, O, and S, each of which is optionally substituted with 1-4 $R^b$ groups;

each $R^b$ is independently H, halogen, CN, hydroxy, $C_{1-4}$ alkyl, $C_{2-4}$ alkenyl, $C_{2-4}$ alkynyl, $C_{1-4}$ alkoxy, $C_{1-4}$ alkoxy-$C_{1-4}$ alkyl, $C_{1-4}$ hydroxyalkyl, $C_{1-4}$ haloalkyl, $C_{1-4}$ haloalkoxy, $-OR^{b4}$, $-NR^{b1}R^{b2}$, $-C(O)R^{b1}$, $-C(O)OR^{b1}$, $-OC(O)R^{b1}$, $-C(O)NR^{b1}R^{b2}$, $-NR^{b1}C(O)R^{b2}$, $-SO_2R^{b1}$, $-SO_2NR^{b1}R^{b2}$, or $C_{3-6}$ cycloalkyl;

alternatively, two $R^b$ groups on adjacent ring atoms can be combined to form a $C_{5-8}$ cycloalkyl or a 5-8 membered heterocycle having 1-2 heteroatoms selected from N, O, and S;

$R^{b1}$ and $R^{b2}$ are each independently H or $C_{1-4}$ alkyl; or $R^{b1}$ and $R^{b2}$ when attached to a nitrogen atom are combined to form a 3-6 membered heterocycle having 1-2 heteroatoms selected from N, O, and S, which is optionally substituted with 1-2 $R^{b3}$;

each $R^{b3}$ is independently H, halogen, $C_{1-4}$ alkyl, or $C_{1-4}$ alkoxy; and

each $R^{b4}$ is independently $C_{1-4}$ hydroxyalkyl, $C_{1-4}$ alkoxy-$C_{1-4}$ alkyl, $C_{3-6}$ cycloalkyl or $C_{3-6}$ cycloalkyl-$C_{1-4}$ alkyl.

~~2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, or an isomer thereof, wherein~~

~~$R^1$ is H or $C_{1-6}$ alkyl;~~

~~$L^1$ is $C_{1-4}$ alkylene;~~

~~$Ar^1$ is a $C_{6-12}$ aryl or 5-10 membered heteroaryl having 1-4 heteroatoms selected from N, O, and S, each of which is optionally substituted with 1-3 $R^a$ groups;~~

~~each $R^a$ is independently H, halogen, $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, $C_{1-4}$ haloalkyl, $C_{1-4}$ haloalkoxy, $-SO_2R^{a1}$, or $-NR^{a1}R^{a2}$;~~

~~$R^{a1}$ and $R^{a2}$ are each independently H or $C_{1-4}$ alkyl; or $R^{a1}$ and $R^{a2}$ when attached to a nitrogen atom are combined to form a 3-6 membered heterocycle having 1-2 heteroatoms selected from N, O, and S, which is optionally substituted with 1-2 $R^{a3}$;~~

~~each $R^{a3}$ is independently H, halogen, $C_{1-4}$ alkyl, or $C_{1-4}$ alkoxy;~~


~~$Ar^2$ is a $C_{6-12}$ aryl or 5-10 membered heteroaryl having 1-4 heteroatoms selected from N, O, and S, each of which is optionally substituted with 1-4 $R^b$ groups;~~

~~each $R^b$ is independently H, halogen, CN, hydroxy, $C_{1-4}$ alkyl, $C_{2-4}$ alkenyl, $C_{2-4}$ alkynyl, $C_{1-4}$ alkoxy, $C_{1-4}$ hydroxyalkyl, $C_{1-4}$ haloalkyl, $C_{1-4}$ haloalkoxy, $-NR^{b1}R^{b2}$, $-C(O)R^{b1}$, $-C(O)OR^{b1}$, $-OC(O)R^{b1}$, $-C(O)NR^{b1}R^{b2}$, $-NR^{b1}C(O)R^{b2}$, $-SO_2R^{b1}$, or $-SO_2NR^{b1}R^{b2}$;~~

~~$R^{b1}$ and $R^{b2}$ are each independently H or $C_{1-4}$ alkyl; or $R^{b1}$ and $R^{b2}$ when attached to a nitrogen atom are combined to form a 3-6 membered heterocycle having 1-2 heteroatoms selected from N, O, and S, which is optionally substituted with 1-2 $R^{b3}$;~~

~~each $R^{b3}$ is independently H, halogen, $C_{1-4}$ alkyl, or $C_{1-4}$ alkoxy.~~

~~3~~2. The compound of claim 1~~ or 2~~, having formula Ia:



(Ia).

~~4. The compound of any one of claims 1 to 3, wherein $Ar^1$ is phenyl or 5-6 membered heteroaryl having 1-4 heteroatoms selected from N, O, and S, each of which is optionally substituted with 1-3 $R^a$ groups.~~

~~5. The compound of any one of claims 1 to 4, wherein $Ar^1$ is phenyl or 5-6 membered heteroaryl having 1-2 heteroatoms selected from N and S, each of which is optionally substituted with 1-2 $R^a$ groups.~~

36. The compound of ~~any one of claims 1 to 5~~claim 1 or 2, wherein $Ar^1$ is phenyl, pyridinyl, or thiazolyl, each of which is optionally substituted with 1-2 $R^a$ groups.

74. The compound of any one of claims 1 to 63, wherein $Ar^1$ is phenyl, which is optionally substituted with 1-2 $R^a$ groups.

~~8. The compound of any one of claims 1 to 7, wherein each $R^a$ is independently H, halogen, CN, $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, $C_{1-4}$ haloalkyl, or $-NR^{a1}R^{a2}$; and $R^{a1}$ and $R^{a2}$ are each independently H or $C_{1-4}$ alkyl.~~


95. The compound of any one of claims 1 to 84, wherein each $R^a$ is independently H, F, Cl, CN, Me, Et, OMe, $CF_3$, $NH_2$, or $N(Me)_2$.

~~10. The compound of any one of claims 1 to 7, wherein each $R^a$ is independently H, halogen, $C_{1-4}$ haloalkyl, or $-NR^{a1}R^{a2}$; and $R^{a1}$ and $R^{a2}$ are combined to form a 3-6 membered heterocycle having 1-2 heteroatoms selected from N and O.~~

116. The compound of any one of claims 1 to 47 and 10, wherein each $R^a$ is independently H, F, $CF_3$, or 1-pyrrolidinyl.

~~12. The compound of any one of claims 1 to 11, wherein $Ar^1$ is phenyl.~~

~~13~~7. The compound of any one of claims 1 to 6~~12~~, having formula Ib:



(Ib).


~~14. The compound of any one of claims 1 to 13, wherein $Ar^2$ is a phenyl or 5-9 membered heteroaryl having 1-4 heteroatoms selected from N, O, and S, each of which is optionally substituted with 1-4 $R^b$ groups.~~

~~15. The compound of any one of claims 1 to 14, wherein $Ar^2$ is a phenyl or 5-9 membered heteroaryl having 1-3 heteroatoms selected from N and S, each of which is optionally substituted with 1-2 $R^b$ groups.~~

8~~16~~. The compound of any one of claims 1 to ~~15~~7, wherein $Ar^2$ is phenyl, pyridinyl, pyrimidiniyl, thiazolyl, pyrazolyl, indazolyl, benzothiazolyl, benzopyrazolyl, or [1,2,4]triazolo[4,3-a]pyridinyl each of which is optionally substituted with 1-2 $R^b$ groups.

~~17. The compound of any one of claims 1 to 16, wherein $Ar^2$ is phenyl, which is optionally substituted with 1-2 $R^b$ groups.~~


~~18~~9. The compound of any one of claims 1 to ~~17~~8, having formula Ic:



(Ic).

~~19. The compound of any one of claims 1 to 16, wherein $Ar^2$ is pyridin-3-yl, which is optionally substituted with 1-2 $R^b$ groups.~~

2010. The compound of any one of claims 1 to 816 and 19, having formula Id:




(Id).

21. The compound of any one of claims 1, and 3 to 20, wherein each $R^b$ is independently H, halogen, CN, $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, $C_{1-4}$ hydroxyalkyl, $C_{1-4}$ haloalkyl, $C_{1-4}$ haloalkoxy, $-OR^{b4}$, $-NR^{b1}R^{b2}$, $-C(O)NR^{b1}R^{b2}$, $-SO_2R^{b1}$, $-SO_2NR^{b1}R^{b2}$, or $C_{3-6}$ cycloalkyl;

$R^{b1}$ and $R^{b2}$ are each independently H or $C_{1-4}$ alkyl; or $R^{b1}$ and $R^{b2}$ when attached to a nitrogen atom are combined to form a 4-6 membered heterocycle having 1-2 nitrogen atoms, which is optionally substituted with 1-2 $R^{b3}$;

each of $R^{b3}$ is independently H, halogen, $C_{1-4}$ alkyl, or $C_{1-4}$ alkoxy; and

each $R^{b4}$ is independently $C_{1-4}$ hydroxyalkyl, $C_{3-6}$ cycloalkyl or $C_{3-6}$ cycloalkyl-$C_{1-4}$ alkyl.

22. The compound of any one of claims 1 to 21, wherein each $R^b$ is independently H, halogen, CN, $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, $C_{1-4}$ hydroxyalkyl, $C_{1-4}$ haloalkyl, or $C_{1-4}$ haloalkoxy.

23. The compound of any one of claims 1, and 3 to 21, wherein each $R^b$ is independently H, F, Cl, CN, Me, Et, nPr, iPr, nBu, iBu, sBu, tBu, OMe, OEt, OnPr, OiPr, $CH_2F$, $CHF_2$, $CF_3$, $CH_2CF_3$, $OCH_2F$, $OCHF_2$, $OCF_3$, $OCH_2CF_3$, $-CH_2OH$, , $-OCH_2CH_2OH$, -O-cyclopropyl, -O-cyclobutyl, -O-cyclopentyl, -O-cyclohexyl, -O-cyclopropylmethyl, -O-cyclobutylmethyl, -O-cyclopentylmethyl, -O-cyclohexylmethyl, $-NH_2$, -NHMe, $-NMe_2$, $-SO_2Me$, $-SO_2Et$, , $-S(O)_2iPr$, $-S(O)_2NHMe$, $-S(O)_2NMe_2$, 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, -C(O)-1-pyrrolidinyl, -C(O)-1-piperidinyl, -C(O)-1-piperazinyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein

~~each of 1-pyrrolidinyl, 1-piperidinyl, and 1-piperazinyl is optionally substituted with 1-2 $R^{b3}$; and~~


~~each $R^{b3}$ is independently H, F, Me, or OMe.~~


~~24~~11. The compound of any one of claims 1~~, 3 to 21 and 23~~ to 10, wherein each $R^b$ is independently H, F, Cl, CN, Me, Et, iBu, OMe, OEt, OiPr, $CF_3$, $OCHF_2$, $OCF_3$, $OCH_2CF_3$, -$CH_2OH$, -$OCH_2CH_2OH$, -O-cyclopropyl, -O-cyclopropylmethyl, -$NMe_2$, -$S(O)_2Me$, -$S(O)_2Et$, -$S(O)_2iPr$, -$S(O)_2NHMe$, -$S(O)_2NMe_2$, 1-pyrrolidinyl, 1-piperidinyl, 4,4-diflouro-1-piperidinyl, 3,3-dimethyl-1-piperidinyl, 3-methyl-1-piperidinyl, 3-methoxy-1-piperidinyl, -C(O)-1-pyrrolidinyl, -C(O)-4-methyl-1-piperazinyl, or cyclopropyl.


~~25~~12. The compound of any one of claims 1 to ~~24~~11, wherein each $R^b$ is independently H, F, Cl, CN, Me, $CF_3$, $OCF_3$, or –$CH_2OH$.


~~26~~13. The compound of any one of claims 1 to ~~25~~12, wherein $R^1$ is H.


~~27~~14. The compound of claim 1, selected from the group consisting of:




,

















,














,
















,






,


,








,

,

,

,

,

,

,

,

,

,

,

,

,

,

,
















,

,

,

,

,

,

,

,

,

,

,

,
















,

,

,

,

,

,

,

,

,

,

,

,

,

,













,

,

,

and .









~~28~~15. The compound of claim 1, selected from the group consisting of:









,

,

,

,

,

,








,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,








,

,

,

,

,

,

,

,

,

,


















,

,

,

,

,

,

,

,

















,

,

,

,

,

,

,







and


~~29~~16. The compound of claim 1, selected from the group consisting of:








,


,

,



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

and .


~~30~~17. The compound of claim ~~27~~14, selected from the group consisting of:

,
,
,
, and
.

18. The compound of claim 14, having the structure


.

19. The compound of claim 14, having the structure





.

20. The compound of claim 14, having the structure





.

21. The compound of claim 14, having the structure





.

22. The compound of claim 14, having the structure





.

23. The compound of claim 14, having the structure





.

24. The compound of claim 14, having the structure





.

25. The compound of claim 14, having the structure





.

26. The compound of claim 15, having the structure





.

27. The compound of claim 15, having the structure




28. The compound of claim 15, having the structure




~~31~~29. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a compound of any one of claims 1 to ~~30~~28.

~~32~~30. ~~A method of treating a disorder or condition through modulating a glucocorticoid receptor, the method comprising administering to a subject in need of such treatment,~~ Use of a therapeutically effective amount of a compound of any one of claims 1 to ~~30~~ 28 or a pharmaceutical composition of claim ~~31,~~29 in the manufacture of a medicament for ~~thereby~~ treating ~~the~~ a disorder or condition through modulating a glucocorticoid receptor.

~~33~~31. ~~A method of treating a disorder or condition through antagonizing a glucocorticoid receptor, the method comprising administering to a subject in need of such treatment,~~ Use of an effective amount of the compound of any of claims 1 to ~~30~~ 28 or a pharmaceutical composition of claim ~~31~~29 in the manufacture of a medicament for treating a disorder or condition through antagonizing a glucocorticoid receptor.

~~34~~32. The ~~method~~ use of claim 31~~33~~, wherein the disorder or condition is selected from the group consisting of obesity, diabetes, cardiovascular disease, hypertension, Syndrome X, depression, anxiety, glaucoma, human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS), neurodegeneration, Alzheimer's disease, Parkinson's disease, cognition enhancement, Cushing's Syndrome, Addison's Disease,

osteoporosis, frailty, muscle frailty, inflammatory diseases, osteoarthritis, rheumatoid arthritis, asthma and rhinitis, adrenal function-related ailments, viral infection, immunodeficiency, immunomodulation, autoimmune diseases, allergies, wound healing, compulsive behavior, multi-drug resistance, addiction, psychosis, anorexia, cachexia, post-traumatic stress syndrome, post-surgical bone fracture, medical catabolism, major psychotic depression, mild cognitive impairment, psychosis, dementia, hyperglycemia, stress disorders, antipsychotic induced weight gain, delirium, cognitive impairment in depressed patients, cognitive deterioration in individuals with Down's syndrome, psychosis associated with interferon-alpha therapy, chronic pain, pain associated with gastroesophageal reflux disease, postpartum psychosis, postpartum depression, neurological disorders in premature infants, and migraine headaches.

~~35~~33. The ~~method~~ use of claim 31~~33~~, wherein the disorder or condition is nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis.

~~36~~34. The ~~method~~ use of claim 31~~33~~, wherein the disorder or condition is an addiction disorder.

~~37~~35. The ~~method~~ use of claim 31~~33~~, wherein the disorder or condition is cancer.